NO20032542L - Dempede anti-CD28-antistoffer og anvendelse derav - Google Patents
Dempede anti-CD28-antistoffer og anvendelse deravInfo
- Publication number
- NO20032542L NO20032542L NO20032542A NO20032542A NO20032542L NO 20032542 L NO20032542 L NO 20032542L NO 20032542 A NO20032542 A NO 20032542A NO 20032542 A NO20032542 A NO 20032542A NO 20032542 L NO20032542 L NO 20032542L
- Authority
- NO
- Norway
- Prior art keywords
- antibodies
- attenuated anti
- attenuated
- Prior art date
Links
- 230000002238 attenuated effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Surgery (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25515500P | 2000-12-14 | 2000-12-14 | |
| PCT/US2001/047955 WO2002047721A1 (en) | 2000-12-14 | 2001-12-14 | Silensed anti-cd28 antibodies and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20032542D0 NO20032542D0 (no) | 2003-06-05 |
| NO20032542L true NO20032542L (no) | 2003-08-07 |
Family
ID=22967074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20032542A NO20032542L (no) | 2000-12-14 | 2003-06-05 | Dempede anti-CD28-antistoffer og anvendelse derav |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1341553A4 (es) |
| JP (1) | JP2004515243A (es) |
| KR (1) | KR20040020866A (es) |
| CN (1) | CN1272345C (es) |
| AR (1) | AR031924A1 (es) |
| AU (2) | AU2608602A (es) |
| BR (1) | BR0116686A (es) |
| CA (1) | CA2432736A1 (es) |
| CZ (1) | CZ20031909A3 (es) |
| HU (1) | HUP0400697A3 (es) |
| IL (1) | IL156262A0 (es) |
| MX (1) | MXPA03005327A (es) |
| NO (1) | NO20032542L (es) |
| NZ (1) | NZ526569A (es) |
| PL (1) | PL363239A1 (es) |
| RU (1) | RU2261723C2 (es) |
| WO (1) | WO2002047721A1 (es) |
| ZA (1) | ZA200305384B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7531168B2 (en) | 2001-02-16 | 2009-05-12 | Genetics Institute Llc | Method for downmodulating immune response in type I diabetes |
| US20080095774A1 (en) * | 2001-02-16 | 2008-04-24 | Wyeth | Agents and Methods for Specifically Blocking CD28-Mediated Signaling |
| ES2776657T3 (es) | 2005-06-14 | 2020-07-31 | Amgen Inc | Formulaciones de proteínas autotamponantes |
| FR2951176A1 (fr) * | 2009-10-09 | 2011-04-15 | Tcl Pharma | Ligands monovalents du recepteur cd28 humain |
| JP5992340B2 (ja) * | 2010-02-18 | 2016-09-14 | エフィミュヌＥｆｆｉｍｕｎｅ | 抗ｃｄ２８ヒト化抗体 |
| WO2018075818A1 (en) | 2016-10-21 | 2018-04-26 | Amgen Inc. | Pharmaceutical formulations and methods of making the same |
| CN112638375A (zh) | 2018-06-15 | 2021-04-09 | 旗舰创业创新五公司 | 通过后细胞信号传导因子的调节来增加免疫活性 |
| JP2022525332A (ja) * | 2019-03-14 | 2022-05-12 | ビオンド バイオロジクス リミテッド | 免疫抑制の方法 |
| MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
| EP4076434A1 (en) | 2019-12-17 | 2022-10-26 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| CN116096906A (zh) | 2020-06-29 | 2023-05-09 | 旗舰创业创新五公司 | 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途 |
| IL300666A (en) | 2020-08-19 | 2023-04-01 | Xencor Inc | ANTI–CD28 COMPOSITIONS |
| US20220325287A1 (en) | 2021-03-31 | 2022-10-13 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| JP2024525475A (ja) | 2021-06-29 | 2024-07-12 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | タノトランスミッションを促進するように操作された免疫細胞及びその使用 |
| KR20240161977A (ko) | 2022-02-23 | 2024-11-13 | 젠코어 인코포레이티드 | 항-CD28 x 항-PSMA 항체 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| EP4598946A1 (en) | 2022-10-05 | 2025-08-13 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| WO2024148336A1 (en) * | 2023-01-06 | 2024-07-11 | Igm Biosciences, Inc. | T cell costimulatory multimeric binding molecules and uses thereof |
| US20240269251A1 (en) | 2023-01-09 | 2024-08-15 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6641809B1 (en) * | 1990-03-26 | 2003-11-04 | Bristol-Myers Squibb Company | Method of regulating cellular processes mediated by B7 and CD28 |
-
2001
- 2001-12-14 RU RU2003121231/15A patent/RU2261723C2/ru not_active IP Right Cessation
- 2001-12-14 CZ CZ20031909A patent/CZ20031909A3/cs unknown
- 2001-12-14 HU HU0400697A patent/HUP0400697A3/hu unknown
- 2001-12-14 BR BR0116686-7A patent/BR0116686A/pt not_active IP Right Cessation
- 2001-12-14 AU AU2608602A patent/AU2608602A/xx active Pending
- 2001-12-14 AR ARP010105828A patent/AR031924A1/es unknown
- 2001-12-14 JP JP2002549291A patent/JP2004515243A/ja not_active Withdrawn
- 2001-12-14 IL IL15626201A patent/IL156262A0/xx unknown
- 2001-12-14 NZ NZ526569A patent/NZ526569A/en unknown
- 2001-12-14 CN CNB018226361A patent/CN1272345C/zh not_active Expired - Fee Related
- 2001-12-14 WO PCT/US2001/047955 patent/WO2002047721A1/en not_active Ceased
- 2001-12-14 EP EP01995504A patent/EP1341553A4/en not_active Withdrawn
- 2001-12-14 MX MXPA03005327A patent/MXPA03005327A/es unknown
- 2001-12-14 KR KR10-2003-7007798A patent/KR20040020866A/ko not_active Ceased
- 2001-12-14 CA CA002432736A patent/CA2432736A1/en not_active Abandoned
- 2001-12-14 AU AU2002226086A patent/AU2002226086C1/en not_active Ceased
- 2001-12-14 PL PL01363239A patent/PL363239A1/xx not_active Application Discontinuation
-
2003
- 2003-06-05 NO NO20032542A patent/NO20032542L/no not_active Application Discontinuation
- 2003-07-11 ZA ZA200305384A patent/ZA200305384B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CZ20031909A3 (cs) | 2003-11-12 |
| EP1341553A1 (en) | 2003-09-10 |
| HUP0400697A2 (hu) | 2004-06-28 |
| RU2261723C2 (ru) | 2005-10-10 |
| CN1272345C (zh) | 2006-08-30 |
| CN1489473A (zh) | 2004-04-14 |
| NO20032542D0 (no) | 2003-06-05 |
| JP2004515243A (ja) | 2004-05-27 |
| ZA200305384B (en) | 2004-10-11 |
| HUP0400697A3 (en) | 2007-05-02 |
| CA2432736A1 (en) | 2002-06-20 |
| BR0116686A (pt) | 2003-12-30 |
| AR031924A1 (es) | 2003-10-08 |
| AU2608602A (en) | 2002-06-24 |
| MXPA03005327A (es) | 2004-12-03 |
| RU2003121231A (ru) | 2005-02-10 |
| WO2002047721A1 (en) | 2002-06-20 |
| EP1341553A4 (en) | 2004-07-28 |
| AU2002226086C1 (en) | 2006-03-09 |
| PL363239A1 (en) | 2004-11-15 |
| IL156262A0 (en) | 2004-01-04 |
| AU2002226086B2 (en) | 2005-08-25 |
| KR20040020866A (ko) | 2004-03-09 |
| NZ526569A (en) | 2005-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20032542D0 (no) | Dempede anti-CD28-antistoffer og anvendelse derav | |
| CY2019029I2 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις | |
| DK1390389T3 (da) | Cripto-blokerende antistoffer og anvendelser deraf | |
| NO20034405D0 (no) | Anti-ostepontin-antistoff og anvendelse derav | |
| IS6779A (is) | Mannlíkt mótefni gegn LT-beta-R | |
| DK1691837T3 (da) | IP-10-antistoffer og anvendelse heraf | |
| DK1417175T3 (da) | Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf | |
| DK1122244T3 (da) | Uracilforbindelser og anvendelse deraf | |
| NO20033418D0 (no) | Immunregulatoriske antistoffer og anvendelse derav | |
| NO20030614L (no) | Anti-IL-12-antistoffer, sammensetninger, fremgangsmåter og anvendelser | |
| IS7041A (is) | 5-HT viðtakabindlar og notkun þeirra | |
| NO20021449D0 (no) | Substituerte 2-tio-3,5-dicyano-4-aryl-6-aminopyridiner og anvendelse derav | |
| TWI316088B (en) | Anti-tnf alpha antibodies and their uses | |
| DK1711207T3 (da) | Interferon-alpha-antistoffer og anvendelse heraf | |
| IS6411A (is) | Kaspasa tálmar og notkun þeirra | |
| FI20002210L (fi) | Rannelaite | |
| NO20033456D0 (no) | Modifiserte og stabiliserte GDF-propeptider og anvendelse derav | |
| NO20033387L (no) | Modifiserte antistoffer og fremgangsmåter for anvendelse | |
| DK1278763T3 (da) | 3-Nitrogen-6,7-dioxygensteroider og anvendelser relateret dertil | |
| FI20002209L (fi) | Rannelaite | |
| DK1339292T3 (da) | Sammensætning og fremgangsmåde | |
| DK1322597T3 (da) | Fremgangsmåde og intermediære | |
| DK1140952T3 (da) | Phosphororganiske forbindelser og anvendelse heraf | |
| DK1317478T3 (da) | Skelnen mellem GnRH-I og GnRH-II | |
| NO20032821D0 (no) | Sea-trosy og beslektede fremgangsmåter |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CREP | Change of representative |
Representative=s name: PLOUGMANN 6 VINGTOFT POSTBOKS 1003 SENTRUM OSLO, 0 |
|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |